IP Library › Granted Patent US 11,850,236
Granted Patent B2
US 11,850,236 · App. 17/809,339 · Granted Dec 26, 2023

Method for inhibiting Zika virus infection

Inventors: Hengli Tang (Tallahassee, FL); Emily M. Lee (Tallahassee, FL); Wei Zheng (Rockville, MD); Ruili Huang (Rockville, MD); Miao Xu (Rockville, MD); Wenwei Huang (Rockville, MD); Khalida Shamim (Rockville, MD); Guoli Ming (Philadelphia, PA); Hongjun Song (Philadelphia, PA)
Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services; Florida State University Research Foundation, Inc.; The Trustees of the University of Pennsylvania
A61K31/4184A61K31/165A61K31/245A61K31/336A61K31/352A61K31/4162A61K31/422A61K31/427A61K31/433A61K31/4535A61K31/4709A61K31/4741A61K31/506A61K31/517A61K31/519A61K31/554A61P31/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,850,236
App. No.
17/809,339
Granted
Dec 26, 2023
Kind
B2
Abstract

The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.

Claims (6)

1. A method for inhibiting Zika virus infection in human or non-human mammalian cells in vitro or in vivo, said method comprising contacting a compound to a human or non-human mammalian cell in vitro or in vivo after exposure of the cell to the Zika virus, wherein the compound has the following chemical structure:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein said contacting is in vitro.

3. The method of claim 1 , wherein said contacting is in vivo.

4. The method of claim 1 , wherein the cell is a human cell.

5. The method of claim 1 , wherein the cell is a non-human mammalian cell.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2022
From: ZHENG, WEI; HUANG, RUILI; XU, MIAO; HUANG, WENWEI; SHAMIM, KHALIDA
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 060809/0048 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2022
From: MING, GUOLI; SONG, HONGJUN
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 060809/0061 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2022
From: TANG, HENGLI; LEE, EMILY M.
To: FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
Reel/Frame 060809/0076 →
Continuity (4)
Continuation 16861281 · Apr 29, 2020
Continuation 16721221 · Dec 19, 2019
Provisional Application 62781687 · Dec 19, 2018
Related Publication 20220362217A1 · Nov 17, 2022